The Combretastatin A-4 (CA-4) Prodrug is a very promising compound now in phase II clinical trials against cancer. CA-4 is acting as a tubulin polymerization inhibitor, preventing cancerous cells from dividing. While performing a structural activity relationship (SAR) study of the antineoplastic compound CA-4, ASU researchers discovered the Phenstatins...